Axel Bex
National Health Service · 656 works · 26,357 citations · h-index 68
Top works
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
- Epidemiology of Renal Cell Carcinoma
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
- Urinary Diversions after Cystectomy: The Association of Clinical Factors, Complications and Functional Results of Four Different Diversions
- Local treatments for metastases of renal cell carcinoma: a systematic review
- Male‐to‐female transsexualism: a technique, results and long‐term follow‐up in 66 patients
- Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
- Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues
- Critical Appraisal of the PADUA Classification and Assessment of the R.E.N.A.L. Nephrometry Score in Patients Undergoing Partial Nephrectomy
- Dynamic Sentinel Node Biopsy in Penile Carcinoma: Evaluation of 10 Years Experience
- Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer